[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-340881-105":59,"doc-detail-340881-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","efficacy-of-immunotherapy-in-her2-mutated-non-small-cell-lung-cancer-a-single-arm-meta-analysis","Efficacy of immunotherapy in HER2-mutated non-small cell lung cancer - a single-arm meta-analysis","","Immune checkpoint inhibitors (ICIs) for non-small cell lung cancer (NSCLC) with HER2 mutations have unclear clinical effectiveness despite their impact on lung cancer care. A systematic search of real-world studies from PubMed, Cochrane Library, and Embase extracted objective response rate (ORR), disease control rate (DCR), and progression-free survival (PFS). Twelve studies with 260 patients showed ORR 0.26, DCR 0.68, and median PFS 5.36 months, with improved outcomes in the combined immunotherapy plus chemotherapy subgroup.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/efficacy-of-immunotherapy-in-her2-mutated-non-small-cell-lung-cancer-a-single-arm-meta-analysis/340881/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/efficacy-of-immunotherapy-in-her2-mutated-non-small-cell-lung-cancer-a-single-arm-meta-analysis/340881.png","ImageObject",300,407,{"name":92,"@type":93},"Logic","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What question does the meta-analysis address for HER2-mutated NSCLC?","Question",{"text":113,"@type":114},"It evaluates the efficacy and safety of immune checkpoint inhibitors in patients with HER2-mutated non-small cell lung cancer, where evidence is still limited.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How were studies selected and what data were extracted?",{"text":118,"@type":114},"Real-world studies were searched in PubMed, Cochrane Library, and Embase, and outcomes including ORR, DCR, and PFS were extracted for analysis.",{"name":120,"@type":111,"acceptedAnswer":121},"What did the pooled results show for ORR, DCR, and PFS?",{"text":122,"@type":114},"Across 12 studies (260 patients), the pooled ORR was 0.26, DCR was 0.68, and median PFS was 5.36 months; the combined immunotherapy plus chemotherapy subgroup had higher ORR and DCR and a longer mPFS.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},340881,1790092934,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":105,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1099513958762,"https://ap-avatar.wpscdn.com/avatar/1000023916a998db790?x-image-process=image/resize,m_fixed,w_180,h_180&k=1784791008015729253","Journal of Cancer Research and Clinical Oncology (2024) 150:42  \n[https://doi.org/10.1007/s00432-023-05509-0](https://doi.org/10.1007/s00432-023-05509-0)  \nEfficacy of immunotherapy in HER2‑mutated non‑small cell lung cancer: a single‑arm meta‑analysis  \nJuguang Zhang1 · Weizhong Han2 · Jun Guo1 · Chufeng Zhang1 · Lijun Cao3 · Lixiu Peng4 · Xiao Han1 · Zhehai Wang1  \nReceived: 2 August 2023 / Accepted: 13 November 2023 / Published online: 27 January 2024 © The Author(s) 2024  \nAbstract  \nBackground Non-small cell lung cancers (NSCLC) harboring Human Epidermal Growth Factor Receptor 2 (HER2) mutations represent a distinct subset with unique therapeutic challenges. Although immune checkpoint inhibitors (ICIs) have been transformative in lung cancer treatment, the efficacy of ICIs in HER2-mutated NSCLC remains to be established.  \nMethods We systematically searched for real-world studies investigating the use of ICIs in treating HER2-mutated NSCLC, sourced from the PubMed, Cochrane Library, and Embase databases. Outcomes including objective response rate (ORR), disease control rate (DCR), and progression-free survival (PFS) were extracted for further analysis.  \nResults Twelve studies involving 260 patients were enrolled in this meta-analysis. Pooled data revealed an ORR of 0.26 (95% CI 0.17–0.34), a DCR of 0.68 (95% CI 0.55–0. 81), and a median PFS (mPFS) of 5.36 months (95% CI 3.50–7.21) . Notably, in the subgroup receiving combined immune and chemotherapy, the ORR increased to 0.37 (95% CI 0.26–0.49), the DCR to 0.79 (95% CI 0 .70–0. 87), and the mPFS to 7.10 months (95% CI 5 .21–8.99) .  \nConclusions ICIs demonstrate promising anti-tumor activity and safety in patients with HER2-mutated NSCLC. Furthermore, the combined regimen of ICIs and chemotherapy may provide a significant therapeutic option for this patient population.  \nKeywords Non-small cell lung cancers · HER2 · Immune checkpoint inhibitors · Efficacy · Meta-analysis  \nIntroduction  \nLung cancer remains a significant global health burden as one of the principal causes of cancer-related mortality, with its prevalence steadily increasing in recent years. Non-small cell lung cancer (NSCLC) represents approximately 80%–85% of all lung cancer cases (Planchard et al.  \n* Xiao Han [hxzbb1983@163.com](hxzbb1983@163.com)  \n* Zhehai Wang [wzhai8778@sina.com](wzhai8778@sina.com)  \nJuguang Zhang  \n[juguangzhang001@163.com](juguangzhang001@163.com)[ ](juguangzhang001@163.com)Weizhong Han [hanweizhong003@163.com](hanweizhong003@163.com)[ ](hanweizhong003@163.com)Jun Guo  \n[jngj2005@126.com](jngj2005@126.com)  \nChufeng Zhang [648110487@qq.com](648110487@qq.com)  \nLijun Cao  \n[306102496@qq.com](306102496@qq.com)  \n2018 ; Sung et al. 2021) . The Human Epidermal Growth Factor Receptor 2 (HER2), a tyrosine kinase receptor of the ERBB/HER family, has emerged as a critical regulator of cell growth and differentiation. Despite lacking a specific endogenous ligand, it activates the downstream PI3KAKT and MEK-ERK signaling pathways to promote cell proliferation(Cheng et al. 2016 ; Ricciardi et al. 2014 ; Yu  \nLixiu Peng  \n[2294714904@qq.com](2294714904@qq.com)  \n1 Department of Medical Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, Shandong, China  \n2 Department of Cardiology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China  \n3 Department of Oncology, Liaocheng Chiping District Hospital of Traditional Chinese Medicine, Liaocheng, Shandong, China  \n4 Department of Internal Medicine, Qilu Hospital of Shandong University, Jinan, Shandong, China  \net al. 2022) . Abnormalities in HER2 signaling can result from HER2 mutations, amplification, or protein overexpression, with HER2 mutations identified in 1%–4% of NSCLC cases(Pillai et al. 2017) .  \nChemotherapy has been the cornerstone treatment for HER2-mutated NSCLC, with previous studies highlighting a median ","cbCaivmlwxLRryDH","https://ap.wps.com/l/cbCaivmlwxLRryDH","pdf",1545982,"English","# Abstract\n# Methods\n## Search strategy\n## Selection criteria\n# Results\n# Conclusions","[{\"question\":\"What question does the meta-analysis address for HER2-mutated NSCLC?\",\"answer\":\"It evaluates the efficacy and safety of immune checkpoint inhibitors in patients with HER2-mutated non-small cell lung cancer, where evidence is still limited.\"},{\"question\":\"How were studies selected and what data were extracted?\",\"answer\":\"Real-world studies were searched in PubMed, Cochrane Library, and Embase, and outcomes including ORR, DCR, and PFS were extracted for analysis.\"},{\"question\":\"What did the pooled results show for ORR, DCR, and PFS?\",\"answer\":\"Across 12 studies (260 patients), the pooled ORR was 0.26, DCR was 0.68, and median PFS was 5.36 months; the combined immunotherapy plus chemotherapy subgroup had higher ORR and DCR and a longer mPFS.\"}]","Efficacy of immunotherapy in HER2-mutated non-small cell lung cancer - a single-arm meta-analysis | PDF",1790039310,28,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d4241eab60bd14dbb219e066cc8e154f.webp",983,1305,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/20cafd30f8c4ebbe9fa2bc18ff2f6788.webp",982,1304,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5dc499821f29e043372ba4ac5954d353.webp",981,1303,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/36e4b1578ba97c95df74b5755edaa4dd.webp",980,1301]